This Centre is located at the Norwegian Institute of Public Health (NIPH) and the main activities of the Centre are drawn up in an agreement between the WHO Headquarters and the Government of Norway. There are also international differences between PDDs, which can be up to four or five fold higher/lower. When there is a substantial discrepancy between the PDD and the DDD, it is important to take this into consideration when evaluating and interpreting drug utilization figures. The PDD will give the average daily amount of a drug that is actually prescribed. DDDs sometimes need to be reviewed because dosages may change over time, e.g. due to the introduction of new main indications or new research making it necessary to change the DDD. Estimating prevalence of drug use in children is not possible by using crude sales data presented in DDDs owing to the variability of children’s doses.

Revisions of the Essential Medicines lists

WHO drug information provides an overview of topics of current relevance relating to drug development and regulation. The Global status report on alcohol and health and treatment of substance use disorders presents a comprehensive overview of alcohol consumption, alcohol-related… WHO recommends that essential medicines, including those that are controlled, be available to all patients at all times at a price that the individual… Access to medicines is essential for attainment of universal health coverage, which is central to achievement of the health-related Sustainable Development…

These guidelines contain recommendations on the identification and management of substance use and substance use disorders for health care services which… Cannabis is globally the most commonly used psychoactive substance under international control. The first edition was published in 2013 and summarized the evidence of drug use prevention at the global level.

This feedback helps WHO develop high-quality guidelines that reflect diverse perspectives and respond to the needs of communities worldwide. To ensure transparency and inclusivity, WHO invites members of the public and interested organizations to review the biographies of the GDG members and provide feedback. GDG members were selected by WHO technical staff based on their technical expertise, their role as end-users (e.g., programme managers and healthcare providers), and their representation of affected communities. In the choice of treatment, WHO recommends OAMT to be used for most patients as the intervention with strongest evidence of effectiveness for variety of outcomes.

WHO guideline on balanced national controlled medicines policies to ensure medical access and safety:…

Quality-assured, safe and effective medicines, vaccines and medicaldevices are fundamental to a functioning health system. Drug dependence treatment and care in the Republic of Serbia Meeting of technical experts on public health responses to cannabis use The publication was invited by resolution 58/5 of the Commission on Narcotic Drugs entitled “Supporting the collaboration of public health and justice… WHO Drug Information provides an overview of topics relating to drug development and regulation that are of current relevance and importance, and includes the lists of proposed and recommended International Nonproprietary Names for Pharmaceutical Substances (INN).

More than 36 million years of healthy life loss (DALY) were attributable to drug use in 2019. Psychoactive drugs are substances that, when taken in or administered into one’s system, affect mental processes, e.g. perception, consciousness, cognition or mood and emotions. English and Spanish versions of the publications are available. Both publications are updated annually and available electronically and in hard copies. The ATC/DDD guidelines and the Index were both published for the first time in the current format in 1990.

  • Such drugs are usually only given one code and this may be a problem for users in countries where other uses are predominant.
  • The challenge occurs when a medicinal product (same strength and route of administration) is approved and used for two or more equally important indications, and the main therapeutic use differs from one country to another.
  • Public expenditure ranges widely between nations, from under 20% of totalhealthcare costs in high-income countries to up to 66% in low-income countries.
  • More than 36 million years of healthy life loss (DALY) were attributable to drug use in 2019.

Drugs (psychoactive)

In the guidelines, WHO recommends the use of a range of treatment options for opioid dependence. Since 1977, WHO has maintained a list of essentialmedicines as a means to promote health equity around the world. At the same time, antimicrobial resistance is challenging the effectiveness of many commonly used medicines in one of the most concerning threats to global health today. Since then there have been incredible advances in drugs for a wide range of health concerns including disease, mental health and other conditions.

Classification principles and challenges

Access to appropriate medications is shown to have substantial impacts on community health and the related economic indicators. Universal health coverage Opioid overdose is easily reversed with the opioid antidote naloxone and with basic life… There is growing concern around the world about drug use and road safety. In 2013, an estimated 181.8 million people aged years… Joint UNESCO, UNODC and WHO publication on education sector responses to substance use in 2017 UNESCO (the United Nations Educational, Scientific and Cultural…

  • The list provides guidance on the development of new and necessary treatments to stop the spread of antimicrobial resistance (AMR).
  • Both publications are updated annually and available electronically and in hard copies.
  • Over 3 million annual deaths due to alcohol and drug use, majority among men
  • In Hanoi, WHO’s collaboration provides a rosy picture of health

These include reduction in non-medical opioid use, mortality and morbidity (including due to opioid overdose, HIV and viral hepatitis), lowering risk of crime and incarceration, better retention in treatment, quality of life and overall wellbeing. To address the issue, WHO has published guidelines for the psychosocially assisted pharmacological treatment of opioid dependence (2009) and community management of opioid overdose (2014). While some 64 million people globally are estimated to live with drug use disorders, access to treatment remains very limited, with less than 10% having access to it. It is crucial that people with opioid dependence and those at risk of opioid overdose have access to prevention, harm reduction, treatment, and care, which are of good quality, affordable, ethical and evidence based. The list provides guidance on the development of new and necessary treatments to stop the spread of antimicrobial resistance (AMR). These include opioid agonist maintenance treatment (or OAMT) with medicines such as methadone and buprenorphine, pharmacological treatment with opioid antagonists (such as naltrexone) as well as psychosocial support.

The World Medicines Situation

High prices, misuse of drugs and poor or unreliabledrug quality contribute to this issue. However, globalized trade can undermine regulation, and in resource-limited settings especially, incidence of substandard or falsified medicines is growing. Today there are thousands of drugs on the market able to prevent, treat and lessen the impact of ailments that would have been fatal just a few generations ago. 1st WHO Forum on alcohol, drugs and addictive behaviours 2nd WHO Forum on alcohol, drugs and addictive behaviours

This list beganwith 208 identified medicines and has grown to include 460 differentpharmaceuticals. WHO works with partners and Member States to strengthen regulation,including post-marketing surveillance, and to eliminate substandard andfalsified medicines. They are thelargest public expenditure on health Drug Treatment and Recovery after personal costs in many low-incomecountries, and the expense is a major cause of household impoverishment anddebt.

The ATC index with DDDs

WHO updates guidelines on opioid dependence treatment and overdose prevention The UNGASS marked a shift in the overall drug policy discourse to highlight the public health and human rights dimensions of the world drug problem and to achieve a better balance between supply reduction and public health measures. About 296 million people aged had used psychoactive drugs in 2021 and about 39.5 million people are estimated to be affected by drug use disorders (harmful pattern of drug use or drug dependence). Psychoactive drugs have different degrees of restriction of availability, depending on their risks to health and therapeutic usefulness, and classified according to a hierarchy of schedules at both national and international levels. This is crucial for mitigating AMR’s impact on public health and the economy. The critical priority pathogens, such as gram-negative bacteria resistant to last-resort antibiotics, and Mycobacterium tuberculosis resistant to the antibiotic rifampicin, present major global threats due to their high burden, and ability to resist treatment and spread resistance to other bacteria.

Opioid agonist maintenance treatment (OAMT) for people with opioid dependence is proven to be safe and effective in addressing a broad range of health… Other high priority pathogens, such as antibiotic-resistant Neisseria gonorrhoeae and Enterococcus faecium, present unique public health challenges, including persistent infections and resistance to multiple antibiotics, necessitating targeted research and public health interventions. Evidence, including systematic reviews, about treatment of opioid dependence and management of opioid overdose will be presented to the GDG. In the guidelines on community management of opioid overdose, WHO recommends that people who are likely to witness an opioid overdose, including people who use opioids, and their family and friends should be given access to naloxone and training in its use so that they can respond to opioid overdose in an emergency.

The World Medicines Situation 2011- Access to controlled medicines, 3rd edition

High priority pathogens, such as Salmonella and Shigella, are of particularly high burden in low- and middle-income countries, along with Pseudomonas aeruginosa and Staphylococcus aureus, which pose significant challenges in healthcare settings. The Framework builds on WHO’s Global health sector strategies and aligns with the Sustainable Development Goals and the Global Action Plan on Antimicrobial Resistance. “Drug resistance threatens decades of progress in HIV, hepatitis and STI control. It emphasizes antimicrobial stewardship, stronger surveillance systems, and equitable access to high-quality prevention, diagnosis and treatment services for HIV, hepatitis B and C and STIs.

Millennium Development Goal 8E aims for affordable access to essential medicines.Essential medicines, as defined by WHO, are those that “satisfy… This report provides a synthesis of the outcomes of the first paediatric drug optimization exercise that was held for Malaria. The PADO for epilepsy exercise aimed to support the identification of short- and long term priorities for epilepsy medicines for the paediatric age group,… WHO’s 6th Virtual cGMP Training Marathon concludes, reinforcing global manufacturing capacities Public expenditure ranges widely between nations, from under 20% of totalhealthcare costs in high-income countries to up to 66% in low-income countries. The price of medicine remains the largest impediment toaccess and the economic impact of pharmaceuticals is substantial.

The updated BPPL incorporates new evidence and expert insights to guide research and development (R&D) for new antibiotics and promote international coordination to foster innovation. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to medicines, making people sicker and increasing the risk of disease spread, illness and deaths. “Together, we can preserve the effectiveness of life-saving antimicrobial drugs and accelerate progress toward ending these epidemics.”

Prescribed Daily Dose (PDD)

Building on the value of the BPPL as a global tool, tailoring the list to country and regional contexts can account for regional variations in pathogen distribution and the AMR burden. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection moving from critical to high priority in BPPL 2024 mirrors recent reports of decreases in global resistance. Gram-negative bacteria have built-in abilities to find new ways to resist treatment and can pass along genetic material that allows other bacteria to become drug-resistant as well.